Geron Operating Cash Flow Sales Ratio from 2010 to 2024
| GERN Stock | USD 4.17 0.11 2.71% |
Check Geron financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Geron's main balance sheet or income statement drivers, such as , as well as many indicators such as . Geron financial statements analysis is a perfect complement when working with Geron Valuation or Volatility modules.
Geron |
About Geron Financial Statements
Geron investors utilize fundamental indicators, such as Operating Cash Flow Sales Ratio, to predict how Geron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Check out the analysis of Geron Correlation against competitors. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.